Abivax S.A. is a French clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for chronic inflammatory diseases. The company's core scientific approach centers on harnessing the body's natural regulatory mechanisms, specifically through the enhanced expression of microRNA-124 (miR-124), to stabilize immune responses. Abivax's pipeline is anchored by its lead drug candidate, obefazimod (formerly ABX464), a first-in-class, once-daily oral small molecule. Obefazimod is currently advancing through Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis, with additional clinical development ongoing for Crohn's disease and potential applications in other inflammatory indications. As a clinical-stage entity, Abivax does not yet generate commercial product revenue and relies on capital markets and strategic partnerships to fund its research and development activities. The company operates primarily out of its headquarters in Paris and its research center in Montpellier, France, while also maintaining a corporate presence in the United States to support its global clinical and regulatory strategy. By targeting fundamental genetic and molecular pathways of inflammation, Abivax aims to provide durable clinical remission and improved tolerability for patients who are underserved by existing biologic and conventional treatments.
